Organon & Co. (NYSE:OGN) PT Raised to $20.00

Organon & Co. (NYSE:OGN) had its target price increased by The Goldman Sachs Group from $18.00 to $20.00 in a research note published on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Separately, Piper Sandler raised their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an overweight rating in a report on Monday, April 29th.

Organon & Co. Price Performance

Shares of OGN stock opened at $20.68 on Friday. The business has a 50-day moving average of $18.19 and a 200 day moving average of $15.76. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08. The stock has a market capitalization of $5.32 billion, a PE ratio of 5.06, a P/E/G ratio of 0.88 and a beta of 0.81.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.55 billion. Analysts anticipate that Organon & Co. will post 4.1 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.42%. Organon & Co.’s dividend payout ratio is presently 27.38%.

Insider Activity at Organon & Co.

In related news, insider Kirke Weaver acquired 2,720 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was acquired at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the acquisition, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.17% of the stock is currently owned by company insiders.

Institutional Trading of Organon & Co.

Large investors have recently bought and sold shares of the company. Lindbrook Capital LLC raised its position in shares of Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after acquiring an additional 1,428 shares in the last quarter. Harvest Fund Management Co. Ltd raised its holdings in Organon & Co. by 495.5% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares in the last quarter. Gladius Capital Management LP lifted its position in Organon & Co. by 65.1% during the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after buying an additional 858 shares during the period. Headlands Technologies LLC bought a new stake in shares of Organon & Co. during the 3rd quarter valued at $35,000. Finally, GAMMA Investing LLC bought a new position in shares of Organon & Co. in the 4th quarter worth about $38,000. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.